Clinical Trials – May 19, 2026
Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.
Funding – May 19, 2026
The company has been awarded funding through the program “Kompetensförstärkning i småföretag 2026.” The funding will support a new project focused on the development planning of a green, dual-use nebulization technology designed for delivery of MucoLife’s lead therapeutic candidate, MLT-001. MLT-001 is a first-in-class inhaled therapy being developed to rapidly dissolve pathological mucus plugs in […]
Intellectual Property – May 19, 2026
The company has received a patent in the United States for its mucoadhesive patch technology, M045A, developed for the treatment of recurrent aphthous stomatitis (mouth ulcers).
Financing – May 18, 2026
The Series B funding will be used to power the company’s AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Pharma Business – May 18, 2026
It has been approved as the first and only aldosterone synthase inhibitor treatment for adults with hypertension.
Pharma article – May 18, 2026
The company is part of a new EU‑funded consortium developing an AI‑ and robotics‑driven manufacturing platform to secure access to critical medicines during shortages and supply chain disruptions.
Clinical Trials – May 19, 2026
Orexo has announced positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with Orexo’s AmorphOX drug delivery technology.
Clinical Trials – May 12, 2026
AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Clinical Trials – May 6, 2026
The independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has been met and recommends that an additional two patients are enrolled at the dose level of 15 MBq/kg to provide a basis for defining a recommended phase II dose and completion of the phase I part of the study.
Clinical Trials – April 24, 2026
Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).
Clinical Trials – April 22, 2026
The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
Clinical Trials – April 22, 2026
The company has announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy.
Confidential
This position is designed for an experienced and ambitious leader who combines strong commercial acumen with the ability to lead, develop, and align teams in a complex healthcare environment.
Cellcolabs AB
We are partnering with Cellcolabs to identify a Chief Medical Officer, who will play a central role in shaping the company’s continued clinical, scientific, and international growth.
Confidential
The position combines strategic account management, in‑field execution and cross‑functional collaboration with Medical Affairs and Market Access.
Confidential
Do you want to shape the future of customer engagement in a global pharmaceutical company? We are looking for a strategic and data-driven Omnichannel Manager to lead the development of integrated communication and marketing initiatives in a highly regulated environment.
Daiichi Sankyo Nordics
Now, we’re looking for a senior HEOR Manager with a solid HTA toolbox who can help secure and expand access to groundbreaking oncology treatments for patients in the Nordics. You will join Daiichi Sankyo, driven by more than 120 years of innovation and a deep global commitment to improving lives.
PharmaRelations
PharmaRelations is the Nordic Market Leader within Talent services for the Life Science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region.
In a new job – May 14, 2026
Finnish Bioindustries Association has elected a new Board of Directors:
In a new job – May 13, 2026
Jane Hvolbæk Nielsen brings, besides an internationally recognized career in materials science research, 15 years of experience in leading and managing a large scientific organisation.
In a new job – May 4, 2026
James Lee brings more than 25 years of experience in the international pharmaceutical and healthcare sector, with a track record of launching innovative medicines and scaling global healthcare brands, according to the company.
Careers article – May 5, 2026
BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech’s partners’ manufacturing capacities and completion of contracts, it states. The company plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac’s sites, affecting up […]
Career choice – April 14, 2026
Anna Carbery’s research looks at how we can implement AI-driven peptide design to make new cancer therapeutics.
Careers article – March 31, 2026
As Sweden crowns its national champions in youth research, the country is grappling with a deeper challenge: how to inspire more young people to pursue science, technology, and maths at a time when PISA results reveal a steady decline in STEM competence across the Nordics.
Profiles in Science – April 22, 2026
It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.
Profiles in Science – March 23, 2026
Dr. Joanna Rorbach, principal researcher at the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, has been awarded the prestigious Göran Gustafsson Prize by the Royal Swedish Academy of Sciences (Kungliga Vetenskapsakademien).
Profiles in Business – December 8, 2025
Successful businessman and former chairman of AstraZeneca, Leif Johansson, has accumulated vast experience and knowledge about international competition, leadership, business development, and entrepreneurship, not least when it comes to science-driven industries like the life science industry.
Pharma Business – May 12, 2026
The Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS smallpox vaccine.
Biotech Business – May 11, 2026
Diamyd Medical has announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.
CDMO – May 5, 2026
The company has established manufacturing capacity in accordance with current quality requirements and regulatory guidelines, it states.
Collaboration – May 11, 2026
Bactiguard Holding has announced an update to its long standing collaboration with license partner BD (Becton, Dickinson & Company) through the signing of a restated long-term agreement.
MedTech Business – May 6, 2026
When Encare was awarded the Swecare Export Award 2026, the company was highlighted as one of the Swedish healthtech companies that has succeeded in translating clinical research into concrete benefits in healthcare internationally.
Intellectual Property – May 4, 2026
Gradientech has received a Notice of Allowance in the United States for its single-use microfluidic test, a key component of the CE marked QuickMIC system.
Biotech Business – May 11, 2026
BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.
Biotech Business – May 11, 2026
Oncopeptides has announced its intention to submit a Type II variation application to the European Medicines Agency (EMA).
Biotech Award – May 11, 2026
The Finnish Bioindustries Biotech Stars Awards were presented at the Made by Cells Biotech Forum on 29 April 2026 at Hanaholmen, Espoo, as part of the celebrations marking the 20th anniversary of Finnish Bioindustries.
Science Award – May 8, 2026
Professor Charlotte Ling of Lund University in Sweden has fundamentally changed the scientific understanding of type 2 diabetes by showing that the disease arises through an interplay between genes and environmental influences that alter which genes are active.
Funding – April 29, 2026
Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.
Science article – April 26, 2026
For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some of the clearest evidence so far that vision loss can be partially restored, not just preserved.
This site uses cookies
